ECOD
X-group (possible homology)

4953 L-aspartase C-terminal domain-like

Open in classification tree →

Ligands and drugs

1,528
Member domains
84
with ligand contacts (≤ 4 Å)
5.5% of members
70
with DrugDomain annotations
4.6% of members
19
with a DrugBank compound
1.2% of members

Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.

Chemical profile

ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.

9
Proteins with classified ligands
7
Superclasses bound (of 23)
—
Superclasses per 20 proteins
fewer than 20 proteins: too few to compare at equal depth

The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.

SuperclassProteinsExpected
0.25×observed / expected4×
RatioSignificance
Homogeneous non-metal compounds41.92.09×not tested
Benzenoids10.71.54×not tested
Organoheterocyclic compounds21.41.47×not tested
Homogeneous metal compounds44.40.92×not tested
Organic acids and derivatives11.40.73×not tested
Organic oxygen compounds11.80.57×not tested
Nucleosides, nucleotides, and analogues12.50.41×not tested
enriched (q < 0.05)depleted (q < 0.05)not significantnot tested (expected < 5)

Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.

DrugBank compounds

DrugBankPDB ligandNameDomains
DB00125ARGArginine1

Most frequently bound compounds

PDB ligandNameDomains in contact
CLCHLORIDE ION15
CAmetalCALCIUM ION8
MGmetalMAGNESIUM ION3
5WJ~{N}-[5-(azepan-1-ylsulfonyl)-2-methoxy-phenyl]-2-(4-oxidanylidene-3~{H}-phthalazin-1-yl)ethanamide2
KmetalPOTASSIUM ION2
KUE~{N}-[5-(azocan-1-ylsulfonyl)-2-methoxy-phenyl]-2-(4-oxidanylidene-3~{H}-phthalazin-1-yl)ethanamide2
KYZ~{N}-[2-methoxy-5-(methylsulfamoyl)phenyl]-2-(4-oxidanylidene-3~{H}-phthalazin-1-yl)ethanamide2
KZ8~{N}-[2-methoxy-5-(phenylsulfamoyl)phenyl]-2-(4-oxidanylidene-3~{H}-phthalazin-1-yl)ethanamide2
KZK~{N}-[5-(azepan-1-ylsulfonyl)-2-methoxy-phenyl]-2-(1~{H}-indol-3-yl)ethanamide2
KZN~{N}-[5-(3,4-dihydro-1~{H}-isoquinolin-2-ylsulfonyl)-2-methoxy-phenyl]-2-(4-oxidanylidene-3~{H}-phthalazin-1-yl)ethanamide2
KZT~{N}-[5-(azepan-1-ylsulfonyl)-2-methoxy-phenyl]-2-quinolin-4-yl-ethanamide2
L0K~{N}-[2-methoxy-5-(1,2,4,5-tetrahydro-3-benzazepin-3-ylsulfonyl)phenyl]-2-(4-oxidanylidene-3~{H}-phthalazin-1-yl)ethanamide2
NAmetalSODIUM ION1